



BFF BANKING
GROUP

Fixed Income Investor Presentation

October 2017

Disclaimer



This presentation may contain written and oral "forward-looking statements", which includes all statements that do not relate solely to historical or current facts and which are therefore inherently uncertain. All forward-looking statements rely on a number of assumptions, expectations, projections and provisional data concerning future events and are subject to a number of uncertainties and other factors, many of which are outside the control of Banca Farmafactoring S.p.A. ("the Company"). There are a variety of factors that may cause actual results and performance to be materially different from the explicit or implicit contents of any forward-looking statements and thus, such forward-looking statements are not a reliable indicator of futures performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise expect as may be required by applicable law. The information and opinions contained in this Presentation are provided as at the date hereof and are subject to change without notice. Neither this Presentation nor any part of it nor the fact of its distribution may form the basis of, or be relied on or in connection with, any contract or investment decision.

The information, statements and opinions contained in this Presentation are for information purposes only and do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to purchase or subscribe for securities or financial instruments or any advise or recommendation with respect to such securities or other financial instruments. None of the securities referred to herein have been, or will be, registered under the U.S. Securities Act of 1933, as amended, or the securities laws of any State or other jurisdiction of the United States or in Australia, Canada or Japan or any jurisdiction where such an offer or solicitation would be unlawful (the "Other Countries"), and there will be no public offer of any such securities in the United States. This Presentation does not constitute or form apart of any offer or solicitation to purchase or subscribe for securities in the United States or the Other Countries.

Pursuant the consolidated law on financial intermediation of 24 February 1998 (article 154-bis, paragraph 2) Carlo Zanni, in his capacity as manager responsible for the preparation of the Company's financial reports declares that the accounting information contained in this Presentation reflects the Banca Farmafactoring S.p.A. documented results, financial accounts and accounting records.

Neither the Company nor any member of the Banca Farmafactoring S.p.A. nor any of its or their respective representatives, directors or employees accept any liability whatsoever in connection with this Presentation or any of its contents or in relation to any loss arising from its use or from any reliance placed upon it.


BFF Banking Group: A Bank Like No Other




General Overview

- **Leading financial services provider to suppliers of the European Healthcare and Public Administration sectors**
- **Three main business lines:**
 - **Non Recourse Factoring (“Purchased”)** (funded business, 82% of gross revenues⁽¹⁾)
 - **Credit Collection Management** (unfunded business, 4% of gross revenues⁽¹⁾)
 - **Financing to healthcare entities and Local Government in CEE** (funded business, 12% of gross revenues⁽¹⁾)
- **Long standing relationship with high profile clients, mainly international and large national companies**
- **Established presence in Spain, Portugal and CEE. First deal in Greece completed in Sept-17**
- **Consistent track record of profitability and cash generation; adjusted RoTE of 30% in 1H 2017⁽²⁾**
- **Low risk profile: NPLs at 0.6% of loans**
- **Sound capital position: CET1 at 13.7%⁽³⁾**


High Profitability and Solid Balance Sheet (1H17)




Net NPLs Ratio (%)



CET1 Ratio (%)



Long and Successful Track Record in a Changing Environment




Leading Provider of Credit Management and Working Capital Solutions to Public Sector Suppliers, to Tackle the Payment Delays From the Public Administration in Southern Europe and CEE




1H17 Customer Loans by geography

€250bn of Public Sector expenditures in the countries we operate in⁽⁴⁾



- Italy NHS
- Italy PA & Other
- Iberia
- Poland
- Other CEE



Source: Eurostat



Notes: (1) Source IPA, Indice delle Pubbliche Amministrazioni; (2) Source IGAE, Intervencion General de la Administracion del Estado; (3) Source Associação Nacional Municípios Portugueses, Direcção Geral do Orçamento and Commissao Nacional de Eleicoes; (4) Exchange rate as of 31/12/16; (5) Data as of 2016.

We Operate in an Underpenetrated €250bn Market, with Leadership Position in Many Geographies...

Key Considerations

- Total potential market is the public sector expenditure in goods & services, c. €250bn in Italy, Spain, Portugal, Poland, Slovakia, Czech Republic and Greece
- In Southern Europe, stable expenditures despite austerity measures
- Growing market in CEE

BFF Positioning



Portugal

- #1 Independent Player
- Sole specialised player in Portugal

Poland

- Leader in alternative financing in Poland

Slovakia

- Sole specialised player in Slovakia





Czech Republic

- One of the few specialist in Czech Republic

Greece

- Sole specialised player in Greece

Total Public Expenditure in Goods and Service (€bn)



1

Solid and Resilient Business Model

- **Resilient profitability across market cycles:** 23% net income CAGR 2013-16, +5% 1H'17-'16⁽¹⁾
- **Long-standing relationship** with top suppliers to the PA (leading multinational and national suppliers)
- **Long track record** in dealing with Public entities and **deep knowledge** of the payment dynamics and strategies
- **Highly experienced** senior management team with a long tenure at the Group (> 12 years on average)

2

Low Risk Profile couple with Strong Capital Position

- c. 99% loan exposure to public and healthcare sector with **CoR of 15 bps and 0.6% net NPL ratio**
- **Diversified and flexible funding base** mainly driven by deposit gathering and wholesale financing
- **Robust capital position** maintained also after the cash acquisition of Magellan, the full 2016 net income pay-out and the Italian downgrade by DBRS in 2017:
 - **1H 2017 Total capital ratio of 19.0%**⁽²⁾, above company target of 15% and +8.25% vs. SREP requirement
 - **1H 2017 CET1 ratio equal to 13.7%**⁽²⁾, more than 2.0x the current SREP requirement of 6.55%
- **LPI stock of €524m** as of June 2017 represents a further buffer to an already strong capital position

3

Robust Profitability with Decreasing Funding Costs


- **Adjusted net income 1H 2017 of €38m** (€51m reported) including Magellan, net of extraordinary items
- **Significantly improved profitability** thanks to an efficient use of capital, with a **1H 2017 RoTE adjusted of 30%**⁽¹⁾
- **Good visibility on further cost of funding reduction**

Solid Business Model...

Suppliers

- Long-standing relationship with top suppliers to the PA (leading multinational and national suppliers) → top 10 clients have been BFF clients for more than 16 years
- Majority of clients have outsourced their credit management activities to BFF → significant barrier to entry
- Significant recurring business with established clients

BFF excl. Magellan Non-Recourse Volumes (€bn)



Recurring clients⁽¹⁾ represented on average more than 70% of total volume



- **Highly experienced senior management team with a long tenure in the Group (> 12 years on average)**



- **Advanced and scalable IT platform developed in-house**




Debtors

- Long track record in dealing with Public entities and deep knowledge of the payment dynamics → better collection
- A proprietary database built over 30 years of experience enabling for an accurate estimate of collection time and credit risk → better pricing
- Short term duration of the receivables purchased allowing constant repricing
- Negligible Cost of Risk
- Low risk of underlying receivables (commercial debt vs. sovereign debt)

...Able to Grow Profitably through Every Season

Net Income (2007-2016)



Fortress Balance Sheet and Low Risk Profile...

Key Considerations

▪ A fortress balance sheet

- Conservative asset / liability management approach: loan book funding duration higher than that of receivables
- Commercial receivables funded through a well diversified funding base with a short maturity of the asset side allowing for fast repricing
- Strong liquidity position with a **LCR of 153%** as of June 2017


Low risk profile

- Negligible credit risk profile: **CoR at c.15 bps**
- Historically recovery of the credit exposure also in default situations


▪ High creditworthiness of the counterparties:

- Mostly multinational and large corporates


Breakdown of Balance Sheet 1H17 (€m)



Cost of Risk (bps)



NPL ratio




... Coupled With a Diversified Funding Base...

Key Considerations


- **Balanced funding profile with deposits accounting for 36% of drawn funds:**
 - €850m deposits gathered as of June 2017, c. 2x versus FY2015
- **Access to capital markets:**
 - €100m Tier 2 5.875% coupon bond issued on 2nd March 2017
 - €200m 5Y senior unsecured 2.0% coupon bond issued on 29th June 2017
- **Group undrawn funding at c. €0.8 bn**

Available Funding⁽¹⁾ (€m)



... and Backed by a Strong Capital Position...

- Robust capital position maintained also after the cash acquisition of Magellan, the full 2016 net income pay-out and the DBRS Italian downgrade
- **Banking Group Total Capital ratio equal to 19.0%**
 - €38m adjusted net income not included in the capital ratios (equal to 206 bps of additional CET1 and total capital) available for dividend distribution
 - 400bps Total Capital in excess of 15% target available to sustain RWA growth
- **Banking Group CET1 ratio of 13.7%**, 2x the CET1 SREP requirement of 6.55%
- **Conservative RWA calculation** based on standard model and with Italian exposure to NHS and other PA risk weighted at 100%⁽²⁾
- **Operational risks RWA will decrease** by c.€38m at the end of 2017 (+0.4% impact on TC ratio and +0.3% on CET1 ratio)




(1) CRR Total Capital Ratio and CET1 Ratio: 15,0% and 10,1%. These ratios are subject to approval by BFF Luxembourg S.à.r.l. (2) Following the DBRS downgrade, starting from March 2017, capital ratios are calculated based on a higher risk weighting factor (from 50% to 100%) for the Italian exposure to NHS and other PA different from local and central government

... With Additional Buffer from LPI Stock

Key Considerations

- **LPI stock represents a further buffer to an already strong capital position**
- **BFF prudentially accounts for LPIs in P&L based on 45% (40% before 2016) recovery rate** (recovery rate has been higher over the last five years) and discounted over a 1,800-day horizon since invoice is due (on average the collection time is shorter)
- **A recent joint statement of Bank of Italy, IVASS and CONSOB⁽¹⁾ upheld BFF's prudential framework for the recognition of the LPI according to the accrual accounting principle**
 - Based on the joint recommendation, the accrual accounting principle is applicable only if a long and deep historical database of payments is available to the company
 - **BFF has a proprietary database built over 30 years of experience in Italy, enabling for an accurate estimate of LPI recovery rate and time**
- **Significant increase in LPI stock in 2016 (+19% vs. 2015) is expected to be visible in the coming years: €524m as of 1H 2017 (+2% vs. 1H 2016)**
- **1H17 unrecognized LPI +6% vs 1H16, adjusted for 45% assumed recovery rate**

LPI Stock Evolution (Excl. Magellan) (€m)




High Profitability and Strong Earnings Growth...



Key Considerations

- Almost doubled net income in the last 4 years to €88m in 2016 (incl. Magellan)
- Significantly improved return on capital thanks to an efficient use of capital with 1H17 RoTE adjusted combined at 30%
- 1H17 adjusted net income (net of extraordinary costs and one-off LPI step-up) reaches €38m, with a +5% growth versus 1H16 including Magellan
- 1H17 adjusted net income is already net of €1.5m of Tier II cost, €1.2m of Magellan acquisition financing cost and €1m of higher taxes related to the reduction of ACE rate
- More than €240m dividend paid between 2013-2016
- Dividend capacity 1H17: distributable income of €38m, +35% y/y growth

Net Income adjusted (€m)




... with Potential for Further Funding Cost Optimization


Key Considerations

- **Reduction in cost of funding continued** with an average cost of funding of 2.04% in 1H17, more than offsetting Tier 2 issuance and Magellan acquisition cost
- **Good visibility on further cost of funding reduction**
 - From 6th June 2017, 12m interest on online deposits offered dropped to 1.00% in Italy and 1.15% in Spain
 - Repayment at maturity of €300m 2.75% coupon 3y bond on 12th June 2017, new €200m 2.0% coupon 5y bond issued on 29th June
 - Further funding synergies at Magellan level thanks to renegotiation of terms and conditions of local funding: 29% of Magellan funding still to be refinanced due to maturity structure


Interest Expenses (€m)



12-months Online Deposits Interest Offered to New Money and Deposit Renewals



Cost of funding (BFF + Magellan - %)



BFF 2020 “Strategic Targets”



BFF BANKING GROUP

The leading provider of credit management and receivables purchasing for the NHS and the Public Administrations Suppliers in the EU

Further consolidate leadership in Italy

- Continue to develop tailor-made offering to serve specific customer needs
- High quality services for large clients covering the full healthcare value chain
- Increase penetration into adjacent segments of non-healthcare suppliers to the NHS and PA
- Invest in IT platform

Further expand business outside Italy both in the NHS and PA, increasing geographical diversification

Maintain a high quality portfolio thanks to a continuous focus on large clients and stringent underwriting standards

- Maintain disciplined underwriting approach
- Continue serving blue-chip customer base

Maintain a solid balance sheet with best-in-class capital position and attractive leverage profile